What is the recommended management for mild to moderate tricuspid regurgitation without symptoms of right‑sided heart failure?

Management of Mild to Moderate Tricuspid Regurgitation Without Symptoms

For asymptomatic patients with mild to moderate tricuspid regurgitation and no evidence of right ventricular dysfunction or significant annular dilatation, conservative management with surveillance echocardiography every 6–12 months is the appropriate strategy. 1

Initial Assessment and Risk Stratification

When evaluating mild to moderate TR, you must systematically assess several key parameters beyond the regurgitation grade itself:

• Measure tricuspid annular diameter on echocardiography; a diameter >40 mm (or >21 mm/m²) indicates significant annular dilatation and changes management even with non-severe TR 2, 1
• Evaluate right ventricular size and systolic function using conventional indices and consider RV free wall longitudinal strain if available 2, 1
• Screen for atrial fibrillation, as persistent AF with mild TR and annular dilatation may warrant more aggressive intervention 2, 1
• Assess for pulmonary hypertension by measuring pulmonary artery systolic pressure, as this influences prognosis and therapeutic strategy 1
• Check for cardiovascular implantable electronic device leads, which can cause or worsen TR 1

Conservative Management Strategy

For truly mild to moderate TR without high-risk features, the following approach is recommended:

• Implement surveillance echocardiography every 6–12 months to monitor for progression of TR severity, RV dilatation, or development of RV dysfunction 1
• Optimize guideline-directed medical therapy if coexisting left ventricular systolic dysfunction is present 2, 1
• Use loop diuretics for volume overload when present, though this addresses symptoms rather than the underlying valve pathology 2, 1
• Consider aldosterone antagonists for additional volume management if right-sided heart failure signs develop 2, 1
• Pursue rhythm control strategies in patients with atrial fibrillation to prevent annular dilatation and TR progression 2

Critical Decision Points for Intervention

The evidence reveals important scenarios where mild to moderate TR should not be managed conservatively:

When Undergoing Concomitant Left-Sided Valve Surgery

If a patient with mild TR is undergoing mitral or aortic valve surgery, concomitant tricuspid valve repair should be considered when:

• Tricuspid annular dilatation is present (>40 mm or >21 mm/m²), even with only mild TR 2, 1
• Persistent atrial fibrillation coexists with mild TR 2
• History of right-sided heart failure is documented 2

This recommendation is supported by strong evidence showing that untreated mild to moderate TR at the time of mitral valve surgery frequently progresses. Research demonstrates that 32% of patients with uncorrected mild to moderate TR showed significant progression by one or more grades postoperatively, accompanied by RV dilatation and decreased ejection fraction 3. A 2023 meta-analysis of 9,813 patients found that concomitant tricuspid repair reduced 30-day mortality (OR 0.66), all-cause mortality (OR 0.40), cardiovascular mortality (OR 0.53), and heart failure hospitalizations (OR 0.41), though at the cost of increased permanent pacemaker implantation (OR 2.09) 4.

Moderate TR with Specific High-Risk Features

For moderate TR specifically, intervention becomes more compelling when:

• Progressive RV dilatation develops despite medical therapy 2, 1
• RV systolic dysfunction emerges on serial imaging 2, 1, 5
• Atrial fibrillation is present with evidence of ongoing RV remodeling 2, 1

Studies show that freedom from moderate-to-severe TR progression in patients with untreated moderate TR at mitral surgery was only 77% at 5 years and 57% at 10 years, with preoperative RV dysfunction (HR 7.2) and age (HR 1.0) as independent predictors of worsening 5.

Common Pitfalls to Avoid

Do not delay referral until severe RV dysfunction or liver cirrhosis develop, as these conditions markedly increase surgical risk and are associated with poor outcomes 2, 1. Irreversible liver cirrhosis is an absolute contraindication to surgery 2.

Do not rely solely on TR grade when making decisions about concomitant repair during left-sided valve surgery; annular diameter and RV function are equally important determinants 5, 6.

Do not assume that mild to moderate TR will remain stable; approximately 25% of patients show progression of at least two grades over time, particularly those with RV dysfunction 5.

Monitoring Parameters

During surveillance, track these specific markers:

• B-type natriuretic peptide levels to assess disease severity and guide therapeutic adjustments 1
• Cardiopulmonary exercise testing in patients who report no symptoms but may have subclinical functional limitations 2, 1
• Cardiac magnetic resonance imaging when echocardiographic windows are inadequate for accurate RV volume and functional assessment 2, 1
• Liver and kidney function tests to detect end-organ damage that would influence surgical candidacy 1

When to Refer

Refer to a multidisciplinary Heart Team at a comprehensive valve center when:

• TR progresses to severe grade on surveillance imaging 1
• RV dilatation or progressive RV dysfunction develops 2, 1
• Symptoms of right-sided heart failure emerge (peripheral edema, ascites, hepatic congestion, reduced exercise tolerance) 1
• Patient is scheduled for left-sided valve surgery and has annular dilatation >40 mm or persistent AF 2, 1

The key principle is that earlier intervention is increasingly favored to prevent irreversible RV injury and end-organ dysfunction 1, but for truly mild to moderate TR without high-risk features, watchful waiting with structured surveillance remains appropriate.